Where does Sunesis Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sunesis Pharmaceuticals, Inc. ranks #13,177 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sunesis Pharmaceuticals, Inc. hold?

Sunesis Pharmaceuticals, Inc. holds 23 US utility patents granted between 2015 and 2021, spanning 14 technology areas.

What is Sunesis Pharmaceuticals, Inc.'s Innovation Score?

Sunesis Pharmaceuticals, Inc. has an Innovation Score of 34.3 out of 100 (top 53% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sunesis Pharmaceuticals, Inc. focus on?

Sunesis Pharmaceuticals, Inc.'s top technology area is C07D (HETEROCYCLIC COMPOUNDS) with 23 patents. Grants appear in 14 CPC subclasses total.

Is Sunesis Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Sunesis Pharmaceuticals, Inc.'s recent grant velocity is -85% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Sunesis Pharmaceuticals, Inc.'s patents?

Sunesis Pharmaceuticals, Inc.'s patents average 16.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sunesis Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Sunesis Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 23 granted patents across 14 technology areas, recorded in grant years 2015–2021. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (HETEROCYCLIC COMPOUNDS).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sunesis ranks #13,177 of 50,000 tracked US assignees by granted-patent volume, with 23 patents across 14 technology areas.

#13,177
of 50,000 US assignees by volume: Top 53%
by Innovation Score (34.3/100): 16.8
avg claims per patent: -85%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13177 · US Corporation #13,177 · 23 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 23 grants
MID-PACK #13,177/50,000
PHOTO-FINISH Spacelabs Healthcare…
CPC-FOCUS C07D · 14 areas
INNOV-THIN 34.3/100
CLAIMS-RICH 16.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -85% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Spacelabs Healthcare L.l.c. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Sunesis Pharmaceutic… · this assignee

34
3D Lighting Innovati… · lowest

7

What this shows Sunesis Pharmaceuticals, Inc. stamps GRANTS-SMALL, MID-PACK, PHOTO-FINISH, CPC-FOCUS, INNOV-THIN, CLAIMS-RICH, TYPE-USCORP, VEL-DROP, BOOK-FULL. Volume places it #13,177 of 50,000; Innovation Score 34.3/100 sits in the top 53% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Spacelabs Healthcare L.l.c. (±0 grants).

Portfolio overview

Sunesis Pharmaceuticals, Inc. has been granted 23 US utility patents between 2015 and 2021, placing Sunesis Pharmaceuticals, Inc. at #13,177 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.8 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a US Corporation, Sunesis Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Sunesis sits between Spacelabs Healthcare L.l.c. (23 patents, rank #13,167) and Sysdig, Inc. (23 patents, rank #13,175) - the closest US assignees by grant volume. The composite Innovation Score of 34.3/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 3 grants, compared with 20 in the 2015–2019 window, a -85% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Sunesis Pharmaceuticals, Inc.'s 16.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 14 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Spacelabs Healthc…

23
Spideroak

23
Study Social

23
Sun Nuclear

23
Sweet Darling Sal…

23
Synexis

23
Syntiant

23
Sysdig

23
Sunesis Pharmaceu… ◀

23

What this shows Sunesis holds 23 patents at rank #13,171, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sunesis

By rank, the assignees closest to #13,171 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Sunesis's primary technology class.

Sunesis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 Top 53% higher than 47% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2021

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Sunesis Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	4.3%
2016	5	21.7%
2017	7	30.4%
2018	7	30.4%
2020	2	8.7%
2021	1	4.3%

Which technologies does Sunesis Pharmaceuticals, Inc. patent most?

C07D - HETEROCYCLIC COMPOUNDS 23

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 20

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 17

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 3

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 2

Y02E - REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION 2

F24S - SOLAR HEAT COLLECTORS; SOLAR HEAT SYSTEMS 2

H10F - INORGANIC SEMICONDUCTOR DEVICES SENSITIVE TO INFRARED RADIATION, LIGHT, ELECTROMAGNETIC RADIATION OF SHORTER WAVELENGTH OR CORPUSCULAR RADIATION 2

H02S - GENERATION OF ELECTRIC POWER BY CONVERSION OF INFRARED RADIATION, VISIBLE LIGHT OR ULTRAVIOLET LIGHT, e.g. USING PHOTOVOLTAIC [PV] MODULES 2

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 2

C12Y - ENZYMES 1

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 1

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 1

Top 14 of 14 technology areas

Where it ranks

Overall rank by patents

#13,177

of 50,000 tracked assignees

Innovation Score

34.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.